GJA1 and breast cancer: Simvastatin cotreatment increases Cx‐43 levels and reduces Cx43 phosphorylation on Ser262 and Ser368 in human breast cancer cells, thus enhancing Doxorubicin cellular accumulation and cytotoxic effects.